hemp
Australia's Hemp Trials Reveal Hard Truths: Industry at Critical Crossroads
The most alarming finding from the trials is the catastrophic variability in imported seed quality.
hyperspectral
Early Leaf Scans Could Revolutionise Cannabis Production
The implications for Australia's emerging cannabis industry are substantial.
Sativex
CNX Therapeutics Acquires Sativex in Strategic CNS Portfolio Expansion
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
OPINION
The Cannabis Paradox: How Australia's Medical Market Boom Became a Domestic Industry Crisis
The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.
Cann Group
Cann Group Secures Major Debt Restructure and $9M Capital Raise
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
tga
From Prohibition to Home Grows: Lessons from Germany's Cannabis Act for Australia's Medical Cannabis Crisis
The contrast between Germany's success and Australia's stagnation raises a fundamental question: what structural differences enable one country to achieve rapid market transformation while another remains locked in gatekeeping and corporate control?
tga
The High Cost of Relief: How Medical Cannabis Pricing Leaves Patients Behind
As health bodies call for crackdown on rogue operators, affordability crisis goes unaddressed.
Ecofibre Limited (ASX: EOF) delisted from the ASX
Ecofibre Limited was an Australian biotechnology company focused on hemp-derived products and technologies. The company listed on the ASX on March 29, 2019, through an IPO that raised $20 million at $1 per share, giving it a market capitalization of $309 million on listing¹. The business was headed by rich-lister
human rights
The Home Cultivation Gap: Comparing Medical Cannabis Access Rights in Australia and Canada
The prohibition creates a two-tiered system where access depends on wealth. Canadian patients can grow unlimited plants based on prescription. Low-income patients aren't excluded due to cost barriers.
OPINION
TGA's Medical Cannabis 'Safety Review': Why Patients Should Be Concerned About Proposed Changes
The consultation does not address home cultivation as a potential solution to affordability concerns, despite this approach being adopted in countries like Canada and several European nations.
australia
Fatal Fungal Contamination Highlights Critical Gap in Medical Cannabis Regulation
A groundbreaking study has provided the first definitive proof that legal medical cannabis can be a deadly source of infection for vulnerable patients.
anthocyanins
Temperature's Impact on Cannabis: New Research Reveals Optimal Growing Conditions for Purple Strains
The research suggests that cannabis cultivators face a trade-off when growing purple varieties.
OPINION
Double the Road Toll, Half the Attention: How Restrictive Cannabis Guidelines May Worsen Australia's Overdose Crisis
Australia's approach to road safety offers valuable lessons for drug policy.
thailand
Thailand’s Cannabis Flip-Flop: Legalisation’s Political Ping-Pong
This duality—strict law, informal leniency—offers a glimpse into what cannabis may become in Thailand: legal enough to use, risky enough to sensationalise.
thailand
Thailand’s Prescription-Only Pivot: A Costly Backstep for Cannabis Reform
Thailand’s Ministry of Public Health estimates 23,000 alcohol-related deaths per year, costing over 1% of GDP. Contrast to cannabis...
420
Roy Morgan Drops Article 420—and It's All About Weed Legalisation
“Australia’s debate on marijuana legalisation continues to evolve. With nearly half of Australians now in favour, the national mood has shifted significantly over the past decade.”